SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of person on diverging path
Career Advice
Back to School? From Industry to Academia
In a tough labor market where layoffs continue, some are considering—or even moving—from industry to academia, according to a BioSpace poll. A career coach, scientist and general practitioner turned research coordinator share their thoughts.
October 17, 2024
 · 
6 min read
 · 
Angela Gabriel
Handshake between man and AI collage. Human and robot hands cropped, isolated on white background. Partnership and teamwork concept, working together.
Artificial Intelligence
AI Is Accelerating Biopharma Innovation But Not Erasing a Human’s Touch
Artificial intelligence won’t replace people in biopharma, but it is infiltrating every step of drug development, including in some ways that aren’t so obvious.
October 16, 2024
 · 
5 min read
 · 
Annalee Armstrong
Deerfield - Circa June 2019: Takeda Pharmaceutical Company. Takeda recently acquired Irish drugmaker Shire I
Huntington’s disease
Takeda Walks Away From Wave Huntington’s Partnership After Sinking $260M in Collaboration
Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on Wave’s WVE-003 clinical-stage Huntington’s disease program—a potential $5 billion commercial opportunity, according to the biotech.
October 16, 2024
 · 
3 min read
 · 
Tristan Manalac
Pastel background. The abstract hand, falling tablets, pills. Artwork or creative collage with art design. Concept of healthcare, covid-19, surrealism, support, medical help, bad habits, drug addiction
Healthcare
As Sanofi Preps Consumer Healthcare Sale, Here’s a Look Back at Similar High-Profile Deals
Sanofi looks to follow a deep history of Big Pharma offloading their consumer healthcare businesses.
October 16, 2024
 · 
6 min read
 · 
Annalee Armstrong
Pictured: GSK laboratories in Dresden, Germany
Patents
GSK Sues Moderna for Alleged Patent Infringement on COVID-19, RSV Vaccines
The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and respiratory syncytial virus shot mResvia.
October 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: J&J's office in Madrid, Spain
Pipeline
J&J Scraps Pipeline Assets Including Alzheimer’s and Parkinson’s Candidates
Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back from the infectious diseases market.
October 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Doctor looks at a chest x-ray film
Lung cancer
Jazz Touts Survival Benefit for First-Line Maintenance Therapy in SCLC
Jazz Pharmaceuticals contends that its alkylating agent Zepzelca significantly improved both overall survival and progression-free survival in patients with extensive-stage small cell lung cancer, when used as a front-line maintenance therapy with Roche’s Tecentriq.
October 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Illustration of woman facing stop signs on way to goal
Resumes & Cover Letters
Career Coach: 10 Resume Mistakes That Might Cost You Your Dream Job
Learn how to craft a resume that stands out by exploring 10 common resume mistakes and how to avoid them.
October 16, 2024
 · 
6 min read
 · 
Carina Clingman
Podcast
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona comes at a bad time for the company; Sen. Warren calls for scrutiny of Novo’s purchase of Catalent; and other news.
October 16, 2024
 · 
1 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS